Antares Pharma — Jefferies 2018 Healthcare Conference
23 slides from Antares Pharma's conference presentation, Jun 5, 2018
Slide 1: Jefferies 2018 Healthcare Conference
NASDAQ: ATRS Jefferies 2018 Healthcare Conference June 5, 2018 Robert F. Apple President and Chief Executive Officer Exhibit 99.1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ mate
Slide 3: Antares Pharma
Antares Pharma A Growing Specialty Pharmaceutical Company With 2017 Revenue of $54.5 Million An Innovative Leader in Self-Administered Injection Technology Novel Drug Delivery Technology Can Provide Multiple Product Opportunities and Life Cycle Management Solutions Strong Balance Sheet - $28.1 Milli
Slide 4: Antares Pharma product overview
Antares Pharma Two combination products approved and on the U.S. market (OTREXUP®, Sumatriptan) AMAG’s Makena® subcutaneous auto injector launched in the U.S. in March 2018 utilizing our QuickShot® device One NDA for a Drug Device Combination Product submitted by Antares to the FDA (XYOSTED™) curren
Slide 5: Proprietary and Partnered Commercial Products
NASDAQ: ATRS Proprietary and Partnered Commercial Products
Slide 6: OTREXUP (methotrexate) injection
OTREXUP® (methotrexate) injection for subcutaneous use 2017 OTREXUP Revenue $17.9 M – expected to continue to grow in 2018
Slide 7: VIBEX Sumatriptan Injection USP
VIBEX® Sumatriptan Injection USP Q118 revenue of $2.8M generated from the shipment/profit sharing of Sumatriptan Injection VIBEX® Sumatriptan Injection USP for acute treatment of migraine and cluster headaches in adults – distributed by Teva *Symphony Health Solutions Quarterly TRx Data 30% 32% Quar
Slide 8: Makena Subcutaneous Auto Injector – FDA Approved
Makena® Subcutaneous Auto Injector– FDA Approved AMAG/Makena® collaboration began in 2014 - Alliance terms: Cost plus product transfer price (fully packaged QuickShot® device), plus royalty on net sales and sales performance milestones QuickShot® device used to develop a once-weekly subcutaneous inj
Slide 9: Makena subcutaneous vs intramuscular injection
Makena® hydroxyprogesterone caproate injection Subcutaneous injection Intramuscular injection Efficient Discreet Administration friendly ü ü ü Makena® - Used to Reduce the Risk of Preterm Birth in Certain At-Risk Women
Slide 10: Proprietary and Partnered Pipeline Products
NASDAQ: ATRS Proprietary and Partnered Pipeline Products
Slide 11: XYOSTED Product Profile
Name XYOSTED™ - Subcutaneous Testosterone Enanthate in an auto injector Dosing Once weekly, single use, fixed dose subcutaneous product Doses 50 mg/0.5 mL TE in solution 75 mg/0.5 mL TE in solution 100 mg/0.5 mL TE in solution Product Features Easy to use and store at room temperature Auto injector
Slide 12: Testosterone Replacement Market: 2015-2018 Retail Prescriptions
Testosterone Replacement Market: 2015-2018 Retail Prescriptions Symphony Health Solutions: Phast IDV 2016 2015 12
Slide 13: XYOSTED Regulatory Update
XYOSTED™ Regulatory Update Received a Complete Response Letter from the FDA on October 20, 2017 The FDA cited two deficiencies: Clinically meaningful increase in blood pressure Concern regarding the occurrence of depression/suicidality Type A meeting held with FDA on February 21, 2018 to discuss CRL
Slide 14: Teva Alliance Development Update
Teva Alliance Development Update Epinephrine Teva filed against EpiPen® (epinephrine) - ANDA still under active review at FDA - ~$22 M pre-launch devices shipped to date Exenatide Teriparatide Teva filed against Byetta® (exenatide) and they are working through the regulatory approval process using t
Slide 15: Recent Quarterly Financial & Operating Results and Upcoming Catalysts
NASDAQ: ATRS Recent Quarterly Financial & Operating Results and Upcoming Catalysts
Slide 16: First Quarter 2018 Financial Results
First Quarter 2018 Financial Results Three Months Ended Mar 31 Increase 2018 2017 (Decrease) Total Revenue $ 12,703 $ 12,007 6% Cost of Revenue 7,186 6,219 16% Gross Profit 5,517 5,788 (5%) % Revenues 43% 48% Research & Development 3,320 3,087 8% S G & A 7,816 7,467 5% Total Operating Expenses 11,13
Slide 17: ZOMAJET Sale to Ferring Pharmaceuticals
ZOMAJET™ Sale to Ferring Pharmaceuticals Needle-free asset sale to Ferring executed October 10, 2017 for up to $14.5 million Milestone Payments: $2.0M paid upon signing in October 2017 $2.75M received Q118 $4.75M received Q218 $5M at Completion (anticipated 2H 2018) Continue to earn royalties and pr
Slide 18: Potential Upcoming Catalysts
Potential Upcoming Catalysts XYOSTED™ PDUFA goal date 9/29/18 – Planning for a Q418 launch if approved Continued growth of OTREXUP® Anticipated growth of Makena® auto injector in 2018 based on AMAG guidance Final payment of $5M anticipated in 2H18 from ZOMAJET™ sale – received $9.5M to date Potentia
Slide 19: Jefferies 2018 Healthcare Conference
NASDAQ: ATRS Jefferies 2018 Healthcare Conference June 5, 2018 Robert F. Apple President and Chief Executive Officer
Slide 20: Appendix I XYOSTED Phase Pharmacokinetic and Safety Results
Appendix I XYOSTED™ Phase 3 Pharmacokinetic and Safety Results
Slide 21: XYOSTED Phase Study Designs
XYOSTED™ Phase 3 Study Designs QST-13-003 – 52-week single arm dose-blinded, concentration controlled multiple-dose, phase III study to evaluate efficacy and safety of XYOSTED™ administered subcutaneously once each week to testosterone-deficient males. The study included a screening phase, a treatme
Slide 22: QST-13-003 PK Data Exceeded all Protocol-Required Outcomes
QST-13-003 PK Data Exceeded all Protocol-Required Outcomes1 Population/Analysis Cavg Lower limit of the 95% 2-sided C. I. C avg % in Range 300 – 1100 ng/dL n (%) Cmax <1500 ng/dL n (%) Cmax >1800 ng/dL n (%) Primary analysis* N=150 87.3% 139 (92.7%) 137 (91.3%)** 0% Completers N=137 94.8% 135 (98.5%
Slide 23: XYOSTED Phase Safety Results
XYOSTED™ Phase 3 Safety Results Previously Published Safety Results QST-13-003 - Adverse reactions (incidence ≥5%) reported were increased hematocrit, hypertension, increased prostate-specific antigen, Upper Respiratory Tract Infection, sinusitis, injection site bruising and headache. SAE’s reported
Antares Pharma — Jefferies 2018 Healthcare Conference on 6ix